2. Search Result
Search Result
Results for "

Ovariectomized

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

15

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0528
    Linarin
    4 Publications Verification

    Buddleoside; Linarine

    		 TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus Infection Neurological Disease Inflammation/Immunology Cancer
    Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer .
    Linarin
  • HY-W009732
    Sinapinic acid
    5 Publications Verification

    Sinapic acid

    		 HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .
    Sinapinic acid
  • HY-113293B
    Estrone sulfate sodium
    3 Publications Verification

    		 Endogenous Metabolite Estrogen Receptor/ERR Metabolic Disease Cancer
    Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research .
    Estrone sulfate sodium
  • HY-13738
    Raloxifene
    Maximum Cited Publications
    20 Publications Verification

    Keoxifene; LY156758 free base; LY139481

    		 Estrogen Receptor/ERR Cancer
    Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
    Raloxifene
  • HY-N2393
    Kukoamine B
    1 Publications Verification

    		 Apoptosis MMP MAPKAPK2 (MK2) p38 MAPK PI3K Akt Reactive Oxygen Species (ROS) DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis .
    Kukoamine B
  • HY-113293A
    Estrone sulfate potassium
    3 Publications Verification

    		 Endogenous Metabolite Estrogen Receptor/ERR Metabolic Disease Cancer
    Estrone sulfate potassium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate potassium is also a substrate of the OATP1B3 transporter. Estrone sulfate potassium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate potassium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate potassium is applicable to breast cancer-related research .
    Estrone sulfate potassium
  • HY-N0026
    2'-Acetylacteoside
    1 Publications Verification

    2'-AA

    		 Monoamine Oxidase RANKL/RANK TNF Receptor NF-κB IKK Cardiovascular Disease Neurological Disease Metabolic Disease
    2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC50 = 17.71 μM, Ki = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease .
    2'-Acetylacteoside
  • HY-N0213
    Peiminine
    Maximum Cited Publications
    7 Publications Verification

    Verticinone; Raddeanine

    		 Autophagy Caspase Bcl-2 Family PARP p38 MAPK ERK NF-κB Apoptosis Inflammation/Immunology Cancer
    Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models .
    Peiminine
  • HY-106019
    Liarozole

    R75251

    		 Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .
    Liarozole
  • HY-107245
    Segetalin B
    2 Publications Verification

    		 Estrogen Receptor/ERR Sirtuin RUNX Metabolic Disease
    Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
    Segetalin B
  • HY-N2135
    Puerarin 6''-O-Xyloside

    		Apoptosis Caspase Bcl-2 Family Tyrosinase Metabolic Disease Cancer
    Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC50 of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar .
    Puerarin 6''-O-Xyloside
  • HY-113293BS1
    Estrone sulfate-d4 sodium

    		Isotope-Labeled Compounds Endogenous Metabolite Estrogen Receptor/ERR Metabolic Disease Cancer
    Estrone sulfate-d4 sodium is the deuterium labeled Estrone sulfate sodium (HY-113293B). Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research .
    Estrone sulfate-d4 sodium
  • HY-121149
    Droloxifene
    1 Publications Verification

    3-Hydroxytamoxifen

    		 Estrogen Receptor/ERR Apoptosis Cancer
    Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats .
    Droloxifene
  • HY-119395B
    Kynuramine dihydrochloride

    		Monoamine Oxidase Metabolic Disease
    Kynuramine, an endogenously occurring amine, is a fluorescent substrate and probe of plasma amine oxidase .
    Kynuramine dihydrochloride
  • HY-121528
    Nilestriol

    Nylestriol; EE3CPE

    		 Estrogen Receptor/ERR Endocrinology
    Nilestriol is a estriol derivative, which inhibits osteoporosis on ovariectomized rats or postmenopausal women .
    Nilestriol
  • HY-110218
    CW 008
    2 Publications Verification

    		 PKA Epigenetic Reader Domain Others
    CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .
    CW 008
  • HY-106019C
    Liarozole dihydrochloride

    R75251 dihydrochloride

    		 Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .
    Liarozole dihydrochloride
  • HY-168336
    E0924G

    		PPAR Metabolic Disease
    E0924G is an orally active activator for PPARδ with EC50 of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models .
    E0924G
  • HY-W009732R
    Sinapinic acid (Standard)

    Sinapic acid (Standard)

    		 Reference Standards HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .
    Sinapinic acid (Standard)
  • HY-113293
    Estrone sulfate

    		Endogenous Metabolite Estrogen Receptor/ERR Metabolic Disease Cancer
    Estrone sulfate is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate is also a substrate of the OATP1B3 transporter. Estrone sulfate can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate is applicable to breast cancer-related research .
    Estrone sulfate
  • HY-119395
    Kynuramine

    Kynurenamine

    		 Monoamine Oxidase Metabolic Disease
    Kynuramine is an endogenous amine that serves as a fluorescent substrate and probe for plasma amine oxidase .
    Kynuramine
  • HY-164587
    E197

    		DOCK Metabolic Disease
    E197 is the inhibitor for DOCK5 that destroys the podosome belt structure of osteoclasts, thereby inhibiting the bone resorption (IC50=3.44 μM in human osteoclast). E197 inhibits the Rac in DOCK5 expressing HEK293 cell with an IC50 of 36 μM. E197 prevents the bone loss in mouse ovariectomized models .
    E197
  • HY-A0114
    Moexiprilat

    RS 10029

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.
    Moexiprilat
  • HY-169703
    SPA0355
    1 Publications Verification

    		 RANKL/RANK p38 MAPK Akt NF-κB Inflammation/Immunology
    SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .
    SPA0355
  • HY-113293BS
    Estrone sulfate-d5 sodium

    		Isotope-Labeled Compounds Endogenous Metabolite Estrogen Receptor/ERR Metabolic Disease Cancer
    Estrone sulfate-d5 sodium is the deuterium labeled Estrone sulfate sodium (HY-113293B). Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research .
    Estrone sulfate-d5 sodium
  • HY-P991365
    DS-1501

    		Transmembrane Glycoprotein Endocrinology
    DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    DS-1501
  • HY-119395A
    Kynuramine dihydrobromide

    		Monoamine Oxidase Metabolic Disease
    Kynuramine dihydrobromide, an endogenously occurring amine, is a fluorescent substrate of plasma amine oxidase .
    Kynuramine dihydrobromide
  • HY-163832
    FPPS-IN-2

    		Farnesyl Transferase Metabolic Disease
    FPPS-IN-2 (compound 4a) is a potent and orally active HFPPS inhibitor with an IC50 value of 1.108 µM. FPPS-IN-2 has the potential for the research of osteoporosis .
    FPPS-IN-2
  • HY-112746
    Etacstil

    DPC974; GW5638

    		 Estrogen Receptor/ERR Cancer
    Etacstil (GW5638) is a estrogen receptor antagonist that displays minimal uterotropic activity in ovariectomized rats and inhibits the agonist activity of Estradiol (HY-B0141), Tamoxifen (HY-13757A) and Raloxifene (HY-13738) in the environment. Etacstil is promising for research of breast cancer and bone protection .
    Etacstil
  • HY-158311
    Anti-osteoporosis agent-8

    		RANKL/RANK p38 MAPK NF-κB Endocrinology
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .
    Anti-osteoporosis agent-8
  • HY-W746269
    KCA 098

    		Drug Derivative Metabolic Disease
    KCA 098 is an orally active benzofuroquinoline derivative. KCA 098 can inhibit bone resorption and stimulat bone formation of chick embryo. KCA 098 can increase calcium and phosphorus content as well as the amount of force required to break the femur from ovariectomized rats. KCA 098 can be used for the research of bone diseases .
    KCA 098
  • HY-106019A
    Liarozole hydrochloride

    R75251 hydrochloride

    		 Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties .
    Liarozole hydrochloride
  • HY-106019CR
    Liarozole dihydrochloride (Standard)

    R75251 dihydrochloride (Standard)

    		 Reference Standards Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (dihydrochloride) (Standard) is the analytical standard of Liarozole (dihydrochloride). This product is intended for research and analytical applications. Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .
    Liarozole dihydrochloride (Standard)
  • HY-106019R
    Liarozole (Standard)

    R75251 (Standard)

    		 Reference Standards Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (Standard) is the analytical standard of Liarozole. This product is intended for research and analytical applications. Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .
    Liarozole (Standard)
  • HY-13738R
    Raloxifene (Standard)

    Keoxifene (Standard); LY156758 free base (Standard); LY139481 (Standard)

    		 Reference Standards Estrogen Receptor/ERR Cancer
    Raloxifene (Standard) is the analytical standard of Raloxifene. This product is intended for research and analytical applications. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
    Raloxifene (Standard)
  • HY-N2393A
    Kukoamine B mesylate

    		Apoptosis MMP MARK PI3K Akt ROS Kinase DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .
    Kukoamine B mesylate
  • HY-N2393S
    Kukoamine B-d5 dihydrochloride

    		MMP Apoptosis MAPKAPK2 (MK2) p38 MAPK PI3K Akt ROS Kinase DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology
    Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with Kd values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .
    Kukoamine B-d5 dihydrochloride
  • HY-117792
    LY314228

    		5-HT Receptor Inflammation/Immunology
    LY314228 is an aminoguanidine 5-HT2 antagonist with relative selectivity for 5-HT2A receptors (IC50: 147.9 nM). The Ki values of LY314228 targeting different 5-HT subtypes are 65 nM (5-HT 2A), 1214 nM (5-HT 2B), and 168 nM (5-HT 2C), respectively. LY314228 is an effective inhibitor of 5-HT-induced paw edema in rats with an ED50 of 6.4 mg/kg in ovariectomized female rats. .
    LY314228
  • HY-114631
    EM-800

    		Estrogen Receptor/ERR Cancer
    EM-800, an orally active anti-estrogen, serves as an antagonist to the transcriptional functions of estrogen receptors α (ERα) and β (ERβ). EM-800 possesses anticancer activity, capable of inhibiting the growth of breast cancer induced by 7,12-Dimethylbenz[a]anthracene (DMBA) (HY-W011845). Furthermore, in ovariectomized animals, EM-800 effectively slows down bone loss. Additionally, EM-800 shows potential in the research of breast and endometrial cancers, while exerting beneficial effects on bone and lipid metabolism .
    EM-800
  • HY-122179
    NUCC-555

    		TGF-β Receptor Inflammation/Immunology
    NUCC-555 is an activin antagonist. NUCC-555 interacts with Trp25, Trp28, Phe55, Tyr93, Lys103, and Asn107 in the Activin A binding pocket. NUCC-555 blocks Activin A-mediated hepatic stellate cells (HSCs) activation. NUCC-555 promotes liver regeneration and halts fibrosis progression in chronic liver disease models. NUCC-555 inhibits Activin A-mediated ovarian cell proliferation. NUCC-555 decreases FSH levels in ovariectomized mice .
    NUCC-555
  • HY-N0213R
    Peiminine (Standard)

    Verticinone (Standard); Raddeanine (Standard)

    		 Reference Standards Autophagy Caspase Bcl-2 Family PARP p38 MAPK ERK NF-κB Apoptosis Inflammation/Immunology Cancer
    Peiminine (Standard) is the analytical standard of Peiminine. This product is intended for research and analytical applications. Peiminine is a compound that can be isolated from Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family). Peiminine can induce apoptosis in human hepatocellular carcinoma HepG2 cells through both extrinsic and intrinsic apoptotic pathways. Peiminine has anti-inflammatory, anticancer, anti-osteoporosis, cardioprotective and other activities in many animal models .
    Peiminine (Standard)
  • HY-113293BR
    Estrone sulfate sodium (Standard)

    		Reference Standards Endogenous Metabolite Estrogen Receptor/ERR Metabolic Disease Cancer
    Estrone sulfate sodium (Standard) is the analytical standard of Estrone sulfate sodium (HY-113293B). This product is intended for research and analytical applications. Estrone sulfate sodium is an inactive endogenous estrogen that can be converted into Estrone (HY-B0234) and Estradiol (HY-B0141). Estrone sulfate sodium is also a substrate of the OATP1B3 transporter. Estrone sulfate sodium can be converted into Estrone and Estradiol in normal mammary parenchymal cells. Estrone sulfate sodium stimulates the growth of nitrosomethylurea-induced mammary tumors in ovariectomized rats and the colony formation of dispersed nitrosomethylurea mammary cells, with conversion into Estrone and Estradiol occurring both in vivo and in vitro during this process. Estrone sulfate sodium is applicable to breast cancer-related research.
    Estrone sulfate sodium (Standard)
  • HY-N2135R
    Puerarin 6''-O-Xyloside (Standard)

    		Reference Standards Apoptosis Caspase Bcl-2 Family Tyrosinase Metabolic Disease Cancer
    Puerarin 6''-O-Xyloside (Standard) is the analytical standard of Puerarin 6''-O-Xyloside (HY-N2135). This product is intended for research and analytical applications. Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC50 of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar .
    Puerarin 6''-O-Xyloside (Standard)
  • HY-138089
    17β-Hydroxy exemestane

    		Androgen Receptor Estrogen Receptor/ERR LDLR Metabolic Disease Cancer
    17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
    17β-Hydroxy exemestane
  • HY-123664
    Trioxifene mesylate

    LY133314

    		 Estrogen Receptor/ERR Cancer
    Trioxifene mesylate (LY133314) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene mesylate binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene mesylate can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma .
    Trioxifene mesylate
  • HY-181682
    NK3R antagonist-1

    		Neurokinin Receptor Endocrinology
    NK3R antagonist-1 is an orally active neurokinin-3 receptor (NK3R) antagonist with an IC50 of 53.61 nM. NK3R antagonist-1 reduces plasma luteinizing hormone (LH) levels in ovariectomized rat models. NK3R antagonist-1 is applicable to research related to menopausal hot flushes .
    NK3R antagonist-1
  • HY-181079
    RANKL-IN-2

    		RANKL/RANK Reactive Oxygen Species (ROS) p38 MAPK NF-κB Metabolic Disease
    RANKL-IN-2 is an orally active RANKL inhibitor with Kd values of 3.21 μM and 4.625 μM in the SPR and MST assays, respectively. RANKL-IN-2 binds to RANKL to interfere with RANKL-RANK interaction. RANKL-IN-2 suppresses osteoclastogenesis by inhibiting ROS, MAPK and NF-κB pathways. RANKL-IN-2 inhibits osteoclastogenesis via inhibition of RANKL-induced osteoclast formation, bone resorption, and osteoclast-specific gene and protein expressions in vitro.RANKL-IN-2 prevents bone loss in ovariectomized osteoporosis mice.RANKL-IN-2 can be used for the research of osteoporosis .
    RANKL-IN-2
  • HY-108979
    Medrogestone

    		Progesterone Receptor Endocrinology
    Medrogestone is an orally active Progestin. Medrogestone shows a marked local progestational effect. Medrogestone maintains pregnancy in ovariectomized rats. Medrogestone inhibits ovulation. Medrogestone prevents pregnancy. Medrogestone produces a significant reduction in the severity of benign prostatic hypertrophy .
    Medrogestone
  • HY-118668
    ABD-350

    		NF-κB Others
    ABD-350 is an antiresorptive agent that inhibits osteoclast activity without affecting osteoblast activity and preventing ovariectomy-induced bone loss. ABD-350 inhibits NF-κB ligand-induced inhibitor of NF-κB phosphorylation, leading to osteoclast apoptosis, but has no inhibitory effect on osteoblast function, effectively preventing bone loss in ovariectomized mice, and does not inhibit parathyroid hormone-induced bone formation.
    ABD-350
  • HY-182818
    SH494

    		p38 MAPK Keap1-Nrf2 Reactive Oxygen Species (ROS) Metabolic Disease
    SH494 is a p38 MAPK inhibitor and Nrf2 pathway activator. SH494 inhibits RANKL-induced phosphorylation of p38 and disrupts the MAPK cascade associated with osteoclastogenesis. SH494 activates the Nrf2 pathway, upregulates downstream target genes and induces the expression of cytoprotective enzymes. SH494 reduces intracellular ROS accumulation and restores mitochondrial membrane potential (ΔΨm) to normal. SH494 decreases osteoclast activity and alleviates osteoporosis symptoms in ovariectomized mice. SH494 can be used for research on osteoporosis .
    SH494

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: